EXACT Therapeutics AS - Minutes from extraordinary general meeting on 13 March 2026

Oslo, 13 March 2026: Reference is made to the stock exchange announcements on 27 February 2026 regarding the exercise of warrants and the extraordinary general meeting to issue the new shares pursuant to the warrants exercise.

The extraordinary general meeting was held today, on 13 March 2026, and all proposals on the agenda were adopted as proposed by the board.

Following issuance of the new shares and exercise of the warrants, the company's share capital will be NOK 446,176.244, divided into 111,544,061 shares, each with a nominal value of NOK 0.004.

Please find enclosed the minutes of the meeting including appendices. The minutes will also be available on the company website: www.exact-tx.com

For more information, please contact: Per Walday, CEO Email per.walday@exact-tx.com John M. Edminson, CFO Email: john.edminson@exact-tx.com About EXACT Therapeutics: EXACT Therapeutics is a clinical-stage precision medicine company utilizing the power of ultrasound to activate the proprietary drug PS101 and enhance the clinical benefit of oncology therapies. PS101 has a unique mode of action and may be combined with a wide range of therapeutic agents within oncology and across a multitude of other indications, including brain diseases. EXACT Therapeutics’ shares are traded on Euronext Growth Oslo (EXTX). Further information may be found here: www.exact-tx.com